Alzheimer's Disease Pipeline Highlights to 2019: H2 2016 Update - Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Preclinical Research, And Discovery Stage - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Alzheimer's Disease Pipeline Highlights - 2016 Update" drug pipelines to their offering.

Alzheimer's Disease Pipeline Highlights - 2016 Update, provides most up-to-date information on key pipeline products in the global Alzheimer's Disease market. It covers emerging therapies for Alzheimer's Disease in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Scope of the Report

Clinical Trial Stages:

The report provides Alzheimer's Disease pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Alzheimer's Disease pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Alzheimer's Disease pipeline products by the company.

Short-term Launch Highlights:

Find out which Alzheimer's Disease pipeline products will be launched in the US and Ex-US till 2019.

Key Topics Covered:

1. Alzheimer's Disease Pipeline by Stages

2. Alzheimer's Disease Pipeline by Drug Class

3. Alzheimer's Disease Pipeline by Company

4. Alzheimer's Disease Phase 3 Clinical Trial Insights

5. Alzheimer's Disease Phase 2 Clinical Trial Insights

6. Alzheimer's Disease Phase 1 Clinical Trial Insights

7. Alzheimer's Disease Preclinical Research Insights

8. Alzheimer's Disease Discovery Stage Insights

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/36nf98/alzheimers

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Alzheimer's Disease Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Alzheimer's Disease Drugs